SCHEDULE: Voss Capital Boosts Stake in Rein Therapeutics to 11.3%

Voss Capital and its affiliates have reported an aggregate beneficial ownership of 11.3% in Rein Therapeutics, Inc. common stock.

Summary

• Voss Capital, L.P. and its affiliated entities, including Voss Value Master Fund, L.P., Voss Value-Oriented Special Situations Fund, L.P., Voss Advisors GP, LLC, and Travis W. Cocke, collectively reported beneficial ownership in Rein Therapeutics, Inc.
• Voss Capital, L.P. and Travis W. Cocke each beneficially own 2,666,532 shares, representing 11.3% of the outstanding common stock.
• Voss Value Master Fund, L.P. beneficially owns 699,440 shares, accounting for 3.0% of the class.
• Voss Value-Oriented Special Situations Fund, L.P. beneficially owns 316,768 shares, representing 1.3% of the class.
• Voss Advisors GP, LLC, as the general partner for the two funds, is deemed to beneficially own 1,016,208 shares, or 4.3% of the class.
• The aggregate percentage of shares is based on 23,547,429 shares outstanding as of August 25, 2025.
• The securities were not acquired for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The filing indicates a significant increase in institutional ownership by a reputable investment firm, which is generally viewed positively as a vote of confidence in the company's prospects. While a 13G is a factual report, the substantial stake suggests a positive outlook from the reporting entity.

Positives

• Increased institutional ownership by Voss Capital and its affiliates may signal confidence in Rein Therapeutics' future prospects.
• The filing explicitly states the acquisition is not for changing or influencing control, which can reduce concerns about activist investor intentions beyond potential nominations.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investor, Voss Capital, has taken a substantial stake in Rein Therapeutics. Such filings are common in the biotech and pharmaceutical sectors, where early-stage companies often attract specialized investment funds. A significant stake by an investment manager like Voss Capital can be viewed as a vote of confidence, potentially attracting further investor interest, especially given the nature of Rein Therapeutics as a biopharmaceutical company.

Comparison to Industry Standards

• An 11.3% stake by an investment firm like Voss Capital is a notable position, often exceeding typical passive investment thresholds and approaching levels where investors might seek board representation or engage in more active dialogue with management. This level of ownership is significant for a single institutional investor group in a publicly traded company, particularly for a smaller-cap or development-stage company like Rein Therapeutics.
• Compared to other institutional holdings in similar biotech companies, an 11.3% stake places Voss Capital among the top shareholders, indicating a high conviction investment.

Stakeholder Impact

• Shareholders: Increased institutional ownership may be perceived positively, potentially boosting investor confidence and liquidity. It could also signal potential for future engagement between the company and a significant shareholder.
• Management: The presence of a large institutional investor like Voss Capital, especially with a stated allowance for Rule 14a-11 nominations, could lead to increased scrutiny or strategic input from this shareholder.

Key Dates

Keywords

Rein Therapeutics, Voss Capital, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Equity Stake, Investment Management